In a retrospective real-world study, 12 patients with RET fusion NSCLC were treated with palivizumab combined with chemotherapy, the ORR was 58%, mPFS was 5.4 months, and OS was 19 months (52). The gene discussed is RET; the disease is non-small cell lung carcinoma.